Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat.
The vanilloid receptor VR1 is a nonspecific Ca(2+) channel, expressed in sensory neurons in the peripheral nervous system and in various brain regions, which is believed to be an important molecular integrator of several chemical (acid, vanilloids) and physical stimuli (heat) that cause pain. Recently, several endogenous ligands for VR1 have been identified such as arachidonyl ethanolamide (anandamide) and the more potent arachidonyl dopamine (AA-DO). Here, we further characterize AA-DO as a ligand for rat VR1, heterologously expressed in CHO and HEK293 cells. AA-DO inhibited the binding of [3H]RTX to VR1 with a K(d) value of 5.49 +/- 0.68 microM and with positive cooperativity (p = 1.89 +/- 0.27), indicating that AA-DO was about 5-fold more potent than anandamide in this system. The K(d) (9.7 +/- 3.3 microM), and p values (1.54 +/- 0.04) for the binding of AA-DO to spinal cord membranes are in good correlation with the CHO-VR1 data. AA-DO stimulated 45Ca(2+) uptake on CHO-VR1 and HEK-VR1 cells with EC(50) values of 4.76 +/- 1.43 and 7.17 +/- 1.64 microM and Hill coefficients of 1.28 +/- 0.11 and 1.13 +/- 0.13, respectively, consistent with the binding measurements. In contrast to anandamide, AA-DO induced virtually the same level of 45Ca(2+) uptake as did capsaicin (90 +/- 6.6% in the CHO cells expressing VR1 and 89.3 +/- 9.4% in HEK293 cells expressing VR1). In a time dependent fashion following activation, AA-DO partially desensitized VR1 both in 45Ca(2+) uptake assays (IC(50) = 3.24 +/- 0.84 microM, inhibition is 68.5 +/- 6.85%) as well as in Ca(2+) imaging experiments (35.8 +/- 5.1% inhibition) using the CHO-VR1 system. The extent of desensitization was similar to that caused by capsaicin itself. We conclude that AA-DO is a full agonist for VR1 with a potency in the low micromolar range and is able to significantly desensitize the cells in a time and dose dependent manner.
Tóth
Attila
A
Molecular Mechanisms of Tumor Promotion Section, Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, National Institutes of Health, Bldg. 37, Rm. 4048, 37 Convent Dr., MSC 4255, Bethesda, MD 20892-4255, USA.
Kedei
Noémi
N
Wang
Yun
Y
Blumberg
Peter M
PM
D000818:Animals; D016718:Arachidonic Acid / Q000494:pharmacology*; D001095:Arachidonic Acids / Q000737:chemistry / Q000494:pharmacology*; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels; D002211:Capsaicin / Q000494:pharmacology; D002460:Cell Line; D006224:Cricetinae; D004224:Diterpenes / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D006801:Humans; D007700:Kinetics; D008024:Ligands; D008956:Models, Chemical; D053284:Polyunsaturated Alkamides; D011485:Protein Binding; D051381:Rats; D011955:Receptors, Drug / Q000737:chemistry* / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects; D013997:Time Factors; D014162:Transfection
D001095:Arachidonic Acids; D015220:Calcium Channels; D004224:Diterpenes; D063388:Endocannabinoids; D008024:Ligands; D053284:Polyunsaturated Alkamides; D011955:Receptors, Drug; C474941:arachidonyl dopamine; D016718:Arachidonic Acid; C024353:resiniferatoxin; D002211:Capsaicin; D002118:Calcium; C078814:anandamide; D004298:Dopamine